Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Ampio Pharmaceutical (AMPE) AMEX

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 43,460
  • Shares Outstanding, K 57,020
  • Annual Sales, $ 1,160 K
  • Annual Income, $ -32,010 K
  • 36-Month Beta 0.20
  • Price/Sales 36.53
  • Price/Book 4.34
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.42
  • Most Recent Earnings N/A on N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.59 +30.51%
on 11/03/16
0.80 -3.75%
on 12/02/16
+0.11 (+16.67%)
since 11/02/16
3-Month
0.59 +30.51%
on 11/03/16
0.97 -20.62%
on 09/08/16
-0.08 (-9.41%)
since 09/02/16
52-Week
0.59 +30.51%
on 11/03/16
4.32 -82.18%
on 05/03/16
-2.77 (-78.25%)
since 12/02/15

Most Recent Stories

More News
Research Reports Initiation on Biotech Stocks -- Pacific Biosciences of California, Marinus Pharma, Emergent BioSolutions and Ampio Pharma

Pre-market, Stock-Callers.com shifts its focus on these four Biotechnology equities: Pacific Biosciences of California Inc. (NASDAQ: PACB), Marinus Pharmaceuticals Inc. (NASDAQ: MRNS), Emergent BioSolutions...

Ampio Announces Accepted Publication of the Clinical Trial Results of Its Oral Drug, Optina(TM), Treatment of Diabetic Macular Edema

Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that a manuscript titled: "Potential Beneficial Effect of Low Dose Danazol in Combination With Renin Angiotensin Inhibitors in Diabetic Macular...

Ampio Updates Clinical and Regulatory Activity

Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced the Company has met with the CBER Division of the FDA to seek guidance on the best path forward to obtain a Biological License for Ampion(TM) to treat...

Ampio Reports Peer-Reviewed Publication on the Potential use of Ampion(TM) in New Clinical Indications

Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced today publication of a scientific peer-reviewed manuscript in the journal Biochemical Biophysical Research Communications entitled: "The low molecular...

Ampio Reports Additional Peer-Reviewed Publication on Ampion(TM)

Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced today publication in the peer-reviewed journal Biochemistry and Biophysics Reports that further describes the modes of action (MOA) of Ampion(TM)...

Ampio Reports Additional Peer-Reviewed Publication on Ampion(TM)

Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced today publication in the peer-reviewed journal Biochemistry and Biophysics Reports that further describes the modes of action (MOA) of Ampion(TM)...

Ampio Pharmaceuticals, Inc. Announces Pricing of Registered Direct Offering

Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has entered into a securities purchase agreement with an institutional investor providing for the registered sale of 5,000,000 shares...

Ampio Pharmaceuticals, Inc. Announces Pricing of Registered Direct Offering

Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has entered into a securities purchase agreement with an institutional investor providing for the registered sale of 5,000,000 shares...

Ampio Updates Regulatory Status of AMPION(TM)

Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced today that it has filed a meeting request and Briefing Document with the FDA to seek guidance on the filing of the company's Biological License Application...

Crohn's Disease (Regional Enteritis) - Pipeline Review Report H2 2015

Research and Markets (http://www.researchandmarkets.com/research/crzbr7/crohns_disease) has announced the addition of the "Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2015" report to their...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

Ampio Pharmaceuticals, Inc. develops proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease, and male sexual dysfunction. Principal products offered by the Company include Optina, an oral drug for the treatment of diabetic retinopathy and macular edema; and Vasaloc,...

See More

Support & Resistance

2nd Resistance Point 0.82
1st Resistance Point 0.80
Last Price 0.77
1st Support Level 0.75
2nd Support Level 0.72

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.